Literature DB >> 9144490

Expression of the murine CD21 gene is regulated by promoter and intronic sequences.

H Hu1, B K Martin, J J Weis, J H Weis.   

Abstract

Murine CD21 gene products are expressed primarily on the surface of B lymphocytes and follicular dendritic cells. To identify the genetic elements that control the tissue-specific expression of the CD21 gene, we analyzed, via transient transfections, the 5' proximal promoter region of the CD21 gene (1272 bp 5' of the initiating ATG). This region possessed strong promoter activity, but it was not tissue specific, in that T cell expression was equivalent to that of B cells. These data suggested that the anticipated tissue-specific control element(s) lies 3' of the initiating ATG. Analysis of a novel minigene construct that possessed both the 5' promoter region and a large region (9 kb) of the CD21 gene 3' of the initiating ATG demonstrated the expected tissue-specific expression. Further analysis using the luciferase reporter system indicated that such control elements reside in the first intron (5.5 kb in size), which separates the exons encoding the signal sequence and the first extracellular short consensus repeat domain of the mature protein. Further dissection of intron 1 demonstrated that the sequences controlling the tissue-specific expression of the murine CD21 gene are contained in the 5' 1.6-kb region of this intron. This 1.6-kb fragment was fractionated into an 800-bp sequence at the 5' end that showed very significant inhibitory activity in both B and T cells and a 3' 800-bp sequence that demonstrated moderate repression in T cells, but enhancer activity in B cells. These data suggest this region of the CD21 gene possesses a number of functionally distinct sites that positively and negatively regulate CD21 gene transcription.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144490

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Complement receptors and the shaping of the natural antibody repertoire.

Authors:  V Michael Holers
Journal:  Springer Semin Immunopathol       Date:  2004-12-22

Review 2.  Molecular structure and expression of anthropic, ovine, and murine forms of complement receptor type 2.

Authors:  Dong Liu; Jian-Ying Zhu; Zhong-Xiang Niu
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

3.  Activation of CD21 and CD23 gene expression by Kaposi's sarcoma-associated herpesvirus RTA.

Authors:  Heesoon Chang; Yousang Gwack; Dior Kingston; John Souvlis; Xiaozhen Liang; Robert E Means; Ethel Cesarman; Lindsey Hutt-Fletcher; Jae U Jung
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Analysis of the regulatory role of BAFF in controlling the expression of CD21 and CD23.

Authors:  Irina Debnath; Kirstin M Roundy; Janis J Weis; John H Weis
Journal:  Mol Immunol       Date:  2006-11-30       Impact factor: 4.407

5.  Heterogeneous nuclear ribonucleoprotein D0B is a sequence-specific DNA-binding protein.

Authors:  M Tolnay; L A Vereshchagina; G C Tsokos
Journal:  Biochem J       Date:  1999-03-01       Impact factor: 3.857

6.  Deletion of putative intronic control sequences does not alter cell or stage specific expression of Cr2.

Authors:  Kirstin M Roundy; Janis J Weis; John H Weis
Journal:  Mol Immunol       Date:  2009-09-09       Impact factor: 4.407

Review 7.  Transcriptional control of complement receptor gene expression.

Authors:  Brian K Martin
Journal:  Immunol Res       Date:  2007       Impact factor: 4.505

8.  Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA.

Authors:  Jian Zhao; Brendan M Giles; Rhonda L Taylor; Gabriel A Yette; Kara M Lough; Han Leng Ng; Lawrence J Abraham; Hui Wu; Jennifer A Kelly; Stuart B Glenn; Adam J Adler; Adrienne H Williams; Mary E Comeau; Julie T Ziegler; Miranda Marion; Marta E Alarcón-Riquelme; Graciela S Alarcón; Juan-Manuel Anaya; Sang-Cheol Bae; Dam Kim; Hye-Soon Lee; Lindsey A Criswell; Barry I Freedman; Gary S Gilkeson; Joel M Guthridge; Chaim O Jacob; Judith A James; Diane L Kamen; Joan T Merrill; Kathy Moser Sivils; Timothy B Niewold; Michelle A Petri; Rosalind Ramsey-Goldman; John D Reveille; R Hal Scofield; Anne M Stevens; Luis M Vilá; Timothy J Vyse; Kenneth M Kaufman; John B Harley; Carl D Langefeld; Patrick M Gaffney; Elizabeth E Brown; Jeffrey C Edberg; Robert P Kimberly; Daniela Ulgiati; Betty P Tsao; Susan A Boackle
Journal:  Ann Rheum Dis       Date:  2014-09-01       Impact factor: 19.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.